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Abstract
Background: Understanding the interaction between viral proteins and neutralizing antibodies at
a t o m i c  r e s o l u t i o n  i s  h i n d e r e d  b y  a  l a c k  o f  experimentally solved complexes. Progress in
computational docking has led to the prediction of increasingly high-quality model antibody-antigen
complexes. The accuracy of atomic-level docking predictions is improved when integrated with
experimental information and expert knowledge.
Methods: Binding affinity data associated with somatic mutations of a rotavirus-specific human
adult antibody (RV6-26) are used to filter potential docking orientations of an antibody homology
model with respect to the rotavirus VP6 crystal structure. The antibody structure is used to probe
the VP6 trimer for candidate interface residues.
Results: Three conformational epitopes are proposed. These epitopes are candidate antigenic
regions for site-directed mutagenesis of VP6, which will help further elucidate antigenic function. A
pseudo-atomic resolution RV6-26 antibody-VP6 complex is proposed consistent with current
experimental information.
Conclusion:  The use of mutagenesis constraints in docking calculations allows for the
identification of a small number of alternative arrangements of the antigen-antibody interface. The
mutagenesis information from the natural evolution of a neutralizing antibody can be used to
discriminate between residue-scale models and create distance constraints for atomic-resolution
docking. The integration of binding affinity data or other information with computation may be an
advantageous approach to assist peptide engineering or therapeutic antibody design.
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Background
The Rotavirus (RV) particle is composed of three concen-
tric viral protein (VP) layers. The intermediate layer con-
sists of VP6 (PDB accession code 1qhd [1]), which is the
most antigenic RV protein in humans. RV is the most
important viral cause of severe dehydrating diarrhea in
infants and young children worldwide. Nearly all children
will be infected with RV before three years of age regard-
less of social or economic status. Moreover, infant anti-
bodies induced by virus exhibit poor functional activity
compared to those of adults. We previously investigated
the human antibody gene repertoire of RV-specific B cells
from infected adults or infants. Although infant antibody
gene sequences used the same immunodominant VH
gene segments as adult sequences to respond to RV, there
was a marked lack of somatic mutations in the infant anti-
body gene sequences [2-4].
Most recently we investigated the kinetic and functional
advantage conferred by naturally occurring somatic muta-
tions in VP6-specific human antibodies [5]. In this study,
we investigated the effect of naturally occurring somatic
mutations on the binding affinity of human antibodies to
VP6. The effect of each somatic mutation in two highly
mutated, naturally occurring adult Fabs (designated RV6-
26 and RV6-25) was determined by mutating the amino
acids one at a time back to the original germline sequence
and measuring the resultant binding affinity. Our results
suggested that the germline sequence codes for a low-
affinity antibody for RV VP6, and somatic mutations in
the HCDR2 region resulted in a higher-affinity adult anti-
body due to a much slower rate of dissociation. In the
present study, our goal is to use data-guided computation
to identify candidate VP6 residues for mutagenesis to fur-
ther clarify the function of the naturally occurring muta-
tions in RV6-26. We use a rational, integrative approach to
identify candidate viral residues for mutagenesis to local-
ize and define the complex surface topology of the major
antigenic site on RV VP6.
Conformational peptides can be determined in detail
from the atomic resolution structure of the antibody-anti-
gen complex, which is most accurately characterized by X-
ray crystallography. Due to difficulties often encountered
in crystallizing complexes, other methods are needed to
characterize the structure of many novel protein-protein
complexes. Cryo-EM is a lower-resolution alternative
when it is not feasible to determine the X-ray structure;
specifically, when the complex has limited ability to form
a crystal or it is difficult to produce sufficient quantities of
the sample. While it is not possible to construct an atomic
resolution structure with cryo-EM alone, the cryo-EM den-
sity can provide valuable insight and can act as a con-
straint for computational docking methods to predict an
atomic-resolution structure. The antibody-antigen dock-
ing problem carried out in this paper is challenging due to
the size of the VP6 trimer, which is composed of 1191 res-
idues (397 for each monomer), and the potential flexibil-
ity of the antibody Fab, which is compose of 227 residues.
However, biological knowledge helps to reduce the size of
the docking search space. For example, it is known that
the lower half of the VP6 is buried inside the RV double-
layered particle and, thus, is not accessible to the antibody
for binding. Docking predictions are most reliable when
prior biological information is incorporated into the
modeling process [6], and site-directed mutagenesis is a
particularly useful source of biological information [7,8].
The diversity of antibodies is due to the six complementa-
rity determining region (CDR) loops, whose flexibility
and large number of surface accessible side chains allow
the antibody to match a particular antigen epitope. When
such induced conformational changes are large, one
expects docking predictions to become less accurate if
backbone flexibility is not incorporated. However, the
large binding affinity of antibody-antigen associations in
general, and the RV6-26-VP6 complex in particular, may
limit the size of conformational shifts upon complex for-
mation due to the evolutionary advantage of constrained
loops for tighter binding [9,10]. We use the protein dock-
ing program RosettaDock [11] to perform simultaneous
Monte-Carlo minimization of backbone displacement
and backbone-dependent side-chain rotamer conforma-
tional changes.
RosettaDock has performed well in the blind Critical
Assessment of Predicted Interactions (CAPRI) protein-
protein docking challenge [12], including a situation in
which one of the docking partners is a homology model
with considerable structural errors [13]. In targets without
significant backbone conformational changes, Rosetta-
Dock modeled nearly all interface side chains accurately
while also finding nearly perfect rigid-body orientations
of the partners. Although most RosettaDock predictions
are performed without the use of prior biological infor-
mation, recently an integrative strategy has been applied
to computational docking of a homology model of an
anti-tumor mAb with the known epitope of the epidermal
growth factor receptor [8]. This filter strategy compared
mutagenesis free energy changes computed by Roset-
taInterface [14] with experimental binding affinity infor-
mation to predict a final structure with reasonable
confidence.
In the current paper, our goal is to identify candidate VP6
epitopes of the human neutralizing antibody RV6-26 by
defining an antibody orientation filter that combines the
distances between interface residues of the docking part-
ners with experimental binding affinity changes due to
site-directed mutagenesis of somatic antibody mutationsImmunome Research 2007, 3:8 http://www.immunome-research.com/content/3/1/8
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back to germline. Unique to this study is the use of
somatic mutations, which occurred during the natural
evolution of an adult human antibody. The orientation
filter is used to select low-resolution RosettaDock model
complexes for refinement. During a low-resolution Roset-
taDock search, each protein is represented as a backbone
with the side chains approximated by their centroids. Dur-
ing a high-resolution search, all side-chain atoms are fully
represented, and we use finer rotational and translational
sampling as described below. After clustering the refined
complexes, the RV6-26 antibody mutation that was most
disruptive for binding following reversion to the germline
sequence (Y66S [5]) acts as a probe for candidate VP6 con-
tact residues.
Methods
Since a crystal structure is not available for mAb RV6-26,
we built a homology model of the structure using the Web
Antibody Modeling (WAM) [15]. WAM uses a large
number of known antibody structures as the knowledge
database for homology modeling, and then applies ab ini-
tio molecular modeling for those parts of the antibody
that are too variable for homology methods. For all dock-
ing runs, we included an alignment of our Fab with anti-
body binding subsequences of known antibody-antigen
complexes, which allows RosettaDock to restrict the anti-
body from assuming an unlikely orientation of its CDR
loops [11].
Figure 1 illustrates the steps of the docking procedure. In
the first step, we started with a complex obtained from a
fit into a cryo-EM density with an approximate resolution
of 22Å [5] and performed 1000 low-resolution Monte-
Carlo simulations with RosettaDock, treating the anti-
body as a rigid body that diffuses toward the fixed VP6
trimer. In applications without a cryo-EM density to seed
the simulations, it may be necessary to perform more than
1000 simulations. The starting structure was obtained by
fitting the X-ray coordinates of the VP6 trimer into the
three-dimensional cryo-EM reconstructions with the Situs
suite of programs [16], and the X-ray coordinates of the
RV6-26 model were fitted into the antibody portion of the
density by visual inspection. Additionally, the CDR loops
of the antibody were oriented toward the VP6. The low-
resolution, residue-scale interaction potentials include
residue-environment and residue-residue interaction
terms derived from a database of interfaces, a contact
score to reward contacting residues, a bump score to
penalize overlapping residues, and an empirical score that
rewards interface CDR residues that are known to make
contact with antigens based on known antibody-antigen
complexes.
In the second step, we used a somatic mutation score
(described below) based on binding affinity changes
measured when naturally occurring RV6-26 antibody
mutations were back-mutated to germline. This score was
used to filter the 1000 low-resolution RosettaDock
decoys. The motivation for using this data as a filter is that
affinity is a measure of the evolutionary fitness of each
mutation that occurs over the course of antibody evolu-
tion. The adult RV6-26 antibody contained 13 somatic
mutations within the heavy chain. To identify which of
these mutations affected binding to VP6, mutant antibod-
ies were produced corresponding to the reversion of each
somatic mutation amino acid back to the germline amino
acid. Somatic mutations also occur in the light chain, but
we focused on the 13 heavy chain mutations because the
VH1–46 is the known immunodominant region. Ref. [5]
provides experimental details of the measured binding
affinity changes between each mutant and the wild-type
RV6-26 antibody. Briefly, each mutant antibody was cre-
ated, expressed, and purified and a detailed kinetic analy-
sis performed using surface plasmon resonance. Most of
the mutants retained binding equivalent to that of the
wild-type Fab except for the six amino acids colored red in
Fig. 2. For the somatic mutation filter in the current study,
we discretized the equilibrium binding affinity changes
for each mutation into active and neutral states (red and
green, respectively, in Fig. 2).
Figure 2 shows the heavy chain amino acid sequences of
the germline and adult RV6-26 antibodies, and summa-
rizes the binding enhancement conferred by each amino
Docking protocol Figure 1
Docking protocol. Docking protocol with somatic muta-
tion binding affinity score that integrates binding affinity data 
from antibody somatic mutations. Blue boxes indicate where 
prior biological information is integrated; yellow boxes indi-
cate the use of low-resolution, residue-scale potentials; and 
green boxes indicate the use of high-resolution, atomic-scale 
potential functions.Immunome Research 2007, 3:8 http://www.immunome-research.com/content/3/1/8
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acid. The numbering scheme used in Fig. 2 is derived from
the immunoglobulin variable (V) gene database (VBASE),
in which a unique antibody amino acid numbering sys-
tem was introduced [17]. The first profile (germ) of the
alignment in Fig. 2 shows the germline heavy-chain
sequence, where the residues highlighted in blue are the
CDR regions. The second profile (6–26) shows the
somatic mutations of the RV6-26 antibody color coded in
terms of their effect on VP6 binding. Amino acids high-
lighted in red were associated with enhanced antiviral
activity of RV6-26, while amino acids highlighted in green
had a neutral effect.
The third profile (TFN) of the alignment in Fig. 2 is the
CDR scoring profile that is part of the low-resolution score
in RosettaDock [11]. For our application, we defined True
(T, orange) residues as CDR residues that are rewarded for
being in the interface; False (F) residues as non-CDR resi-
dues that have not been observed to make antigen contact
in known complexes and are penalized for being in the
interface; and Neutral (N) interface residues as rarely
occurring contact residues and non-CDR active residues,
which make no contribution to the score. Even though the
RV6-26 residues Gly73, Leu90, and Ser92 are not CDR res-
idues, they were labeled as Neutral in the TFN profile
because they were experimentally found to be active
somatic mutations. This neutral labeling prevents the
CDR score from excluding these non-CDR active somatic
mutations from the interface.
For each complex, we created a matrix D of pair-wise dis-
tances between the Cα atoms of the 13 residue mutations
of the RV6-26 antibody and a collection of VP6 residues
from the interface, chosen based on visual inspection of
the cryo-EM density. Virus interface residues were selected
for the filter from two of the three VP6 chains: B-chain res-
idues 197–213, 253–282, 287–301, 304, and 308; and C-
chain residues 157–173, 236–247, and 351–374. The
rows of the matrix D correspond to theVP6 residues at the
interface and the columns to the antibody mutations
highlighted in Fig. 2. For a given complex, we can deter-
mine the shortest distance of each antibody mutation to
the VP6 interface from the matrix D. These distances yield
a vector d whose elements are given by
whose length is equal to the number of antibody muta-
tions.
dD i
j
ij = min (1)
Antibody binding affinity map Figure 2
Antibody binding affinity map. Heavy-chain amino acid sequences for germline and RV6-26 adult antibodies, and the Roset-
taDock CDR scoring profile (TFN). Regions likely to be at the interface (CDRs) are highlighted in blue for the germline 
sequence. Active mutations in RV6-26, which result in improved binding with VP6, are highlighted in red, while neutral or neg-
ative mutations are highlighted in green. The TFN sequence is the RosettaDock scoring profile defined for this study that 
rewards True (T, orange) interface residues in the CDR region known to make contact with antigens, penalizes False (F) inter-
face residues not observed to make antigen contact, and makes no contribution for Neutral (N) interface residues that rarely 
make contact with antigens and non-CDR active residues.
10 . 20 . 30 . 40 .
germ EVQLVESGAEVKKPGASVKVSCKASGYSFTSYYVHWVREA4 7
6-26 EVQLVESGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQA4 7
TFN FFFFFFFFFFFFFFFFFFFNNNNNTTTTTTTTTTNNNNNF4 7
50 . 60 . 70 . 80 .
germ PGEGLEWMGMINPSDGSTSYAQRFQPRVTMTRDTSTTTVF8 7
6-26 PGQGLEWMGIINPSGGSTYYAQKFQGRVTMTRDTSTSTVY 87
TFN FFFFFNNNNTTTTTTTTTTNNNNNNNNNFFFFFFFFFFFN8 7
90 . 100 . 110 . 120 .
germ MEMSGLRSEDTAVYYCARGVVGATNEIDFWGQGTTVTVS 126
6-26 MELSSLRSEDTAVYYCARGVVGATNEIDFWGQGTTVTVS 126
TFN NNNNNNNNFFFFNNNTTTTTTTTTTTTNNNFFFFFFFFF 126Immunome Research 2007, 3:8 http://www.immunome-research.com/content/3/1/8
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The filter score F of a complex is given by the following
sum over all antibody mutations M (M = 13 for RV6-26)
where the contribution from each residue is
and dc is a distance cutoff in Angstroms that characterizes
our measure of closeness between the antibody and anti-
gen. We classify a somatic mutation as "active" if back-
mutation to germline has a disruptive effect on binding to
the antigen. "Neutral" somatic mutations are non-disrup-
tive when mutated back to germline. In Eq. (3a), an active
somatic mutation contributes 1 to the affinity filter score
of a complex if this residue is within dc Angstroms of the
antigen interface. In our application, we chose a relatively
loose cutoff of dc= 12Å to allow all active mutations the
possibility of contributing to the score, including ones
that may be more distant from the interface. It has been
observed that many affinity-maturing mutations in singe
chain Fv antibodies correspond to residues that are more
distant from the interface [18,19]. A smaller cutoff would
exclude the contribution to the score of residues that are
involved in affinity maturation yet may not make direct
contact with the antigen. In Eq. (3b), we allow a neutral
or negative somatic mutation to contribute 1/2 to the
score if it is more distant from the interface than dc. This
essentially penalizes neutral somatic mutations that are
closer to the interface than the cutoff distance. Of course,
it is still possible for non-disruptive mutations to be near
the interface, so this soft distance constraint penalizes but
does not exclude neutral residues from contacting the
antigen. In the final piece (Eq. 3c), all other somatic muta-
tions do not contribute to the filter score of Eq. (2).
In the third step of Fig. 1, we performed a high-resolution
docking refinement of the top filtered complexes. A back-
bone-dependent rotamer packing algorithm is used for
side-chain repacking [20]. From each of the best low-res-
olution complexes ranked by filter score, we created 200
high-resolution decoys using the perturbation triplet (2Å,
2Å, 20°). This perturbation triplet represents a search vol-
ume with respect to the line connecting the protein cent-
ers. The first number refers to translation along the line,
the second refers to translation in the plane perpendicular
to the line, and the third refers both to rotation around
the axis defined by the line and tilt relative to the axis.
The resulting high-resolution decoys were ranked accord-
ing to their full-atom scores. Candidate complexes were
determined by an additional round of refinement (1Å, 1Å,
10°) following k-medoids (k = 3) clustering of the top
Rosetta-scoring complexes. Root-mean-square deviation
(RMSD) of the alpha-carbon coordinates was used as the
cluster metric, and the cluster location was given by the
decoy with the lowest full-atom energy score within the
cluster. We used k-medoids clustering because, unlike
hierarchical clustering, it does not require linkage
assumptions, and it is simpler than mixture model cluster-
ing. Unlike model-based clustering, which has the advan-
tage of a statistical model that allows it to estimate the
number of clusters, we must a priori choose the number of
clusters in k-medoids; however, this choice is easily vali-
dated by visual inspection of the 3D complexes. The can-
didate binding sites were determined from the final
candidate complexes by finding the VP6 residues within a
5Å radius of the RV6-26 Tyr66. This mutation was chosen
as a computational probe because it had the largest effect
on binding affinity as back-mutation of this residue
resulted in an 83-fold decreased rate of dissociation [5].
Results
Following the creation of 1000 antibody-antigen decoy
complexes with the fit into the cryo-EM density map in
Ref. [5] as a starting structure, we calculated the somatic
mutation affinity score (Eq. 2) of each complex for the fil-
ter in step 2 of Fig. 1. Because six somatic mutations were
labelled active and seven as neutral, the maximum affinity
filter score is 9.5. The highest score of the low-resolution
complexes was 9.0. Figure 3 shows the top low-resolution
RV6-26-VP6 complexes clustered by affinity filter score. As
the filter score of the complexes increases, the RMSD tight-
ens between complexes within the same cluster. This sug-
gests that the level of uncertainty in the location of the
binding partners decreases with increasing somatic muta-
tion affinity score.
Starting from the best 45 filtered low-resolution com-
plexes from the top four clusters in Fig. 3, we created 200
high-resolution decoys each. The resulting 9000 high-res-
olution decoys were ranked according to their energy
scores. We created the 9000 high-resolution decoy com-
plexes by searching a small region of space defined by (2Å,
2Å, 20°) around each low-resolution starting complex.
We then ranked the high-resolution decoys by full-atom
score and k = 3 medoid clustered the top 100 with a pair-
wise RMSD metric. The location of two of the three clus-
ters corresponded to the top two full-atom scores, and the
location of the third cluster corresponded to the fourth
full-atom ranked structure. This third cluster had very
close RMSD with one of the other two clusters, so we
chose the top two complexes for a final refinement step
(200 decoys searched in a volume defined by 1Å, 1Å, and
Ff d di
i
M
c =
=
∑ ()
1
(2)
fd
ddi
ddi di
ic
ic c()
,
,
,
=
≤∧ ∈
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1
1
2
active (3a)
neutral (3b)
0o t h e r rwise (3c)





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10°). The best refinements of these two clusters, along
with a repacked and minimized structure of the best-scor-
ing (F = 9.0) low-resolution complex in Fig. 3, represent
the three candidate modes of binding summarized in Fig.
4.
In Fig. 4, the VP6 residues shaded green are within a 5Å
radius of the RV6-26 Tyr66 of each candidate mode of
binding. For clarity, only the Tyr66 residues are repre-
sented from the antibodies. These tyrosines in red act as
computational probes of VP6 residues. Our approach has
the effect of marching these probes up the outer sheet of
the neck of one of the VP6 monomers. The probes in Fig.
4 allow us to propose VP6 residues for mutation and
measurement of binding affinity changes to discriminate
between the candidate modes of binding. The antibody
probes suggest the following VP6 residues for mutation
and binding affinity measurement to test whether they
contribute to the antigenic site that is the target for bind-
ing by the RV6-26 antibody: Glu262, Leu264, Gln268,
Ile269, Gln274, Arg289, Met295, Arg296, Pro297, and
Pro298.
The best scoring high-resolution model, shown in Fig. 5
and magnified in Fig. 6, is proposed as the Ab-Ag complex
most consistent with current experimental information.
The complex in Fig. 5 corresponds to the uppermost tyro-
sine along the VP6 neck in Fig. 4. The Model in Fig. 5 and
6 suggests that the epitope residues nearest the Tyr66 anti-
body residue are Met295, Arg296, Pro297, and Pro298.
These and the other proposed conformational epitope res-
idues are shaded orange. In Figs. 5 and 6, four of the six
active antibody residues are within 5Å of the interface;
namely, Ile57, Gly62, and Tyr66 from CDR2 (see also Fig.
2) and Gly73. All six active antibody residues are within
12Å of the interface.
Discussion
In this study, we proposed an integrative structure-based
computational approach to identify the RV VP6 epitope
for a human adult antibody. Successful computational
docking strategies have been developed that integrate
experimental data, such as NMR chemical shift perturba-
tions, residual dipolar couplings, and mutagenesis data
[6]. In these strategies, experimental information typically
Affinity filter clusters Figure 3
Affinity filter clusters. Top low-resolution complexes clustered according to filter score (FS). (a) FS = 7.5, (b) FS = 8.0, (c) 
FS = 8.5, (d) FS = 9.0. The RV6-26 Fv chains are shaded blue (light chain) and green (heavy chain). The RMSD of the clusters 
tightens as the score improves (increases).Immunome Research 2007, 3:8 http://www.immunome-research.com/content/3/1/8
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i
s used either as a filter to validate docked complexes or a
wrapper to restrain potential complexes during sampling.
For example, HADDOCK incorporates biologic informa-
tion as an additional energy term to be minimized during
sampling [21,7]. To increase the power to identify the cor-
rect binding site, the strategy used in the current paper
integrated knowledge-based restraints into the modeling
process before, during and after docking; using, respec-
tively, a cryo-EM density, CDR alignment score, and bind-
ing affinity data for somatic mutations. The cryo-EM
density was used to constrain the starting point for dock-
ing simulations, and the CDR information was used to
restrict unrealistic antibody orientations during docking
runs. We combined experimental binding affinity
changes, which quantify the evolutionary fitness of each
mutation, with soft distance constraints estimated from
the cryo-EM. We integrated this information into a score
for each complex that acts as a post-processing filter after
the docking models were created. The best, filtered com-
plexes underwent high-resolution refinement then clus-
tering to give three candidate binding modes.
This strategy is unique in its use of naturally occurring
somatic mutations of a human antibody as a filter. The
fact that all six active antibody residues were within 12Å
of the interface (Fig. 5) corroborates the self-consistency
of our choice of distance cutoff in the somatic mutation
score (Eq. 2). A loose distance restraint was chosen due to
previous observations that active residues often do not
make direct contact with antigen [18,19]. The somatic
Magnification of proposed high-resolution antibody-antigen  complex Figure 6
Magnification of proposed high-resolution antibody-
antigen complex. Magnified 3D atomic structure of Fig. 5 
complex centered on the candidate interface. The light chain 
is hidden, which otherwise obscures the interface. Active 
heavy chain somatic mutations and VP6 virus residues that 
make contact with the Y66 antibody residue are labelled.
Candidate binding sites Figure 4
Candidate binding sites. Candidate residues involved in 
antibody-antigen (RV6-26-VP6) binding as predicted from the 
three best computational docking refinements. The antibod-
ies for the three complexes are hidden except for the tyro-
sines (red), which act as probes for detecting candidate viral 
residues for mutagenesis (green). VP6 side chains (all in the 
same monomer) that are within 5Å of a tyrosine probe are 
shown in green.
Proposed high-resolution structure of antibody-antigen com- plex Figure 5
Proposed high-resolution structure of antibody-anti-
gen complex. Best-scoring high-resolution (RV6-26-VP6) 
complex. The heavy chain of the RV6-26 Fab is shaded green 
and the light chain blue. Interface VP6 residues on chain B 
within 5Å of the active antibody residues are shaded orange. 
The active Fab residues that most affect binding affinity upon 
back-mutation have side chains shaded red. The CDR2 loop, 
which contains half of the active residues, is also shaded red.Immunome Research 2007, 3:8 http://www.immunome-research.com/content/3/1/8
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mutation score was used as a post-docking complex filter
not unlike the filter used in Ref. [8] in which computa-
tional and experimental mutagenesis results were com-
pared. In this study, we used RosettaDock, but the somatic
filter score could be used with other docking programs.
Another strategy worth pursuing is to use the somatic
mutation score as a wrapper as opposed to a filter, which
would involve wrapping the somatic mutation score into
the energy function during sampling to obtain a collec-
tion of complexes enriched for active residues in the inter-
face. A simple way to implement a wrapper with
RosettaDock would be to use the CDR alignment profile.
In the applied result in this paper, the algorithm had the
advantage of an initial distance constraint provided by a
cryo-EM density. This gave us added confidence in the
antigenic-site candidates found by the algorithm, and it
provided a starting point for validation of the algorithm
on complexes where only binding affinity data is known.
Unlike the two candidate complexes (whose antibody
tyrosines were further down the VP6 neck in Fig. 4), the
final complex in Fig. 5 is entirely within the cryo-EM den-
sity map (data not shown). However, to avoid undue bias
from the cryo-EM, we retain the other, less conservative
complex predictions as candidate mutagenesis sites on the
VP6 to validate in a subsequent study. If a cryo-EM density
were not available, a reasonable strategy would be to sim-
ulate a large (105) number of low-resolution complexes to
explore the global space of potential interfaces, and then
choose an encompassing region around the largest cluster
as the VP6 residues near the interface.
Affinity changes measured for the reversion of somatic
mutations provides information about interface residues
but not about specific antigen contacts. Additional feed-
back with experiment is necessary to unambiguously
identify the interface. Thus, binding affinity changes
caused by directed mutagenesis of the proposed viral pro-
tein residues will be used to eliminate false positive
epitopes that we suspect in the less conservative com-
plexes. Once residues from the epitope have been identi-
fied through this process, binding affinity changes from
VP6 mutagenesis will be used together with the naturally
evolved somatic mutations of the RV6-26 antibody that
enhance binding affinity (Fig. 2) to infer distance con-
straints for a more accurate prediction of the complex
than Fig. 5. The resolution of our final model in Fig. 5 is
diminished by the potential error in the antibody homol-
ogy model. After we obtain distance constraints from the
VP6 mutagenesis follow-up study, we will perform con-
formational sampling of the antibody loop, constrained
at the active site, to account for errors in the antibody
homology model and loop conformational changes that
may occur upon binding.
In addition to conformational epitope identification,
computational docking that integrates experimental data
may lead to more general in silico procedures for the pre-
diction of antibody mutations that produce higher affin-
ity, higher specificity binding to a desired target
macromolecule than the natural antibody sequence. Stud-
ies involving the in vitro evolution of antibodies have
shown that the diversity of structurally stable antibody
sequences is much greater than the diversity observed in
nature, which suggests that this diversity could be
exploited for therapeutic antibody design [22,23]. Com-
putation coupled with feedback to experimental informa-
tion is a promising in silico-in vitro integrative approach to
guide the design or enhancement of therapeutic antibod-
ies.
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